XSHE
002550
Market cap1.19bUSD
Oct 09, Last price
6.52CNY
1D
0.15%
1Q
-5.09%
Jan 2017
-9.70%
IPO
27.84%
Name
Changzhou Qianhong Biopharma Co Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Changzhou Qianhong Biopharma CO.,LTD operates as a key player in China's biopharmaceutical sector, specializing in the research, development, production, and distribution of biological drugs, with a core focus on enzyme and polysaccharide-based compounds. The company's product lineup features a variety of active pharmaceutical ingredients (APIs). These include a range of anticoagulants such as heparin sodium, heparin calcium, enoxaparin sodium, nadroparin calcium, and dalteparin sodium, alongside pancreatin for digestive aid, asparaginase for antineoplastic applications, kallidinogenase kallikrein for treating microcirculation disorders, and heparinoid. Furthermore, Changzhou Qianhong provides ready-to-administer preparations, like pre-filled syringes of nadroparin calcium, enoxaparin sodium, and dalteparin sodium, all used as anticoagulants. It also supplies asparaginase injections for cancer treatment and heparin sodium injections to prevent blood clots. The company extends its reach through the export of its products internationally. Founded in 1971, Changzhou Qianhong Biopharma CO.,LTD maintains its headquarters in Changzhou, China.
Key people
Yi Yao
Finance Director, Secretary of the Board · since 2024
Ke Wang
General Manager, Director · since 2017
Tao Hai
Deputy General Manager · since 2017
Xiang Zhou
Deputy General Manager, Director · since 2024
Jie Huang
General Director · since 2024
Chunwei Mei
General Director · since 2024
Guming Wang
General Director · since 2024
Lijun Wei
General Director · since 2024
Hongping Ye
General Director · since 2024
Shaobo Zou
General Director · since 2024
Yong Fan
Chief Quality Officer · since 2011
Aiqun Xiao
Chief Audit Officer · since 2024
Chizhou Jiang
Deputy General Manager, Director · since 2024
Yaofang Wang
Chairman of the Board · since 2008
Gang Zhao
Vice Chairman of the Board · since 2017
Yuyu Gao
Independent Director · since 2024
Ao Ning
Independent Director · since 2024
Shengxiang Ren
Independent Director · since 2024
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||